Brenntag reports strong earnings for Q3 2012

Published: 9-Nov-2012
Ingredients Finance

Third quarter sales grew by 5.4% to €2.47m


Global chemicals distributor Brenntag has announced a strong third quarter performance with sales increasing by 5.4%, based on constant exchange rates, to €2.47m. Gross profit was also revealed to have grown by 4% to €493.2m overall for the company.

Steve Holland, ceo of Brenntag, commented on the results: “We are very pleased with the development of our gross profit in the third quarter which was achieved under challenging market conditions around the world.

“The very positive development of our share price which topped the €100m mark for the first time confirms our strategy and motivates us further to implement it with all our energy.”

  • Companies:
  • Brenntag
See more

You may also like

Distribution

Brenntag acquires OWI Chlor Alkali

Read more
Brenntag has announced the acquisition of OWI Chlor Alkali (Old World Specialty Chemicals and Old World Logistics) from Old World Industries in Northbrook (IL, US)

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  3. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Distribution

Brenntag acquires OWI Chlor Alkali

Brenntag has announced the acquisition of OWI Chlor Alkali (Old World Specialty Chemicals and Old World Logistics) from Old World Industries in Northbrook (IL, US)
Distribution

Brenntag becomes exclusive distributor for INOFEA services in EMEA

INOFEA has developed the enzzen technology, enhancing enzyme stability, enabling recyclability and easy recovery in manufacturing steps
Distribution

Brenntag issues promissory note for $641m

The chemicals and ingredients distribution specialist plans to use the proceeds to finance business development
Media

Brenntag North America announces collaboration with Umicore

The partnership will focus on the distribution of polyurethane and polyester catalysts
Ingredients

Evonik and Brenntag to co-operate on hydrogen peroxide and peracetic acid for pharma and cosmetics markets

Evonik will market specialised hydrogen peroxide (PERSYNT) and peracetic acid (PERACLEAN) products
Ingredients

Brenntag opens head office in India

To take advantage of growth potential in Indian market
Ingredients

Brenntag reports ‘robust performance with strong results’

Operating EBITDA up 13.4% in first half 2011
Subscribe now